Is it time to pick up some PSYK, PSY and PSIL ETFs?
"Given the strong results, Compass Pathways plans to move ahead with a late-stage clinical trial of psilocybin, likely using the 25-milligram dose, but that detail still needs to be discussed with regulators. The recent trial was a so-called Phase 2B trial, which was intended to figure out the appropriate dose; the next trial, a Phase 3, will test that chosen dose in a larger group."
Where do we sign up?